secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001140361-25-005080
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M
--------------------------------------------------------------------------------

- FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.
- WAINUA launched Jan 2024: $85M product sales, $20M royalties; 84% QoQ growth in Q4.
- TRYNGOLZA approved Dec 19, 2024 for FCS; first independent launch underway.
- Donidalorsen PDUFA date Aug 21, 2025 for HAE; OLE data shows 96% sustained mean attack rate reduction.
- 2025 guidance: revenue >$600M, non-GAAP op loss <$495M, cash ~$1.7B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/0001140361-25-005080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/ef20043828_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer